Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Reversal of experimental Laron Syndrome by xenotransplantation of microencapsulated porcine Sertoli cells.

Luca G, Calvitti M, Mancuso F, Falabella G, Arato I, Bellucci C, List EO, Bellezza E, Angeli G, Lilli C, Bodo M, Becchetti E, Kopchick JJ, Cameron DF, Baroni T, Calafiore R.

J Control Release. 2013 Jan 10;165(1):75-81. doi: 10.1016/j.jconrel.2012.08.028. Epub 2012 Sep 3.

PMID:
22964394
2.

A cell therapy-based cure of the Laron Syndrome.

Park K.

J Control Release. 2013 Jan 10;165(1):90. doi: 10.1016/j.jconrel.2012.11.018. No abstract available.

PMID:
23218447
3.

Generation of a miniature pig disease model for human Laron syndrome.

Cui D, Li F, Li Q, Li J, Zhao Y, Hu X, Zhang R, Li N.

Sci Rep. 2015 Oct 29;5:15603. doi: 10.1038/srep15603.

4.

Long-term stability, functional competence, and safety of microencapsulated specific pathogen-free neonatal porcine Sertoli cells: a potential product for cell transplant therapy.

Luca G, Mancuso F, Calvitti M, Arato I, Falabella G, Bufalari A, De Monte V, Tresoldi E, Nastruzzi C, Basta G, Fallarino F, Lilli C, Bellucci C, Baroni T, Aglietti MC, Giovagnoli S, Cameron DF, Bodo M, Calafiore R.

Xenotransplantation. 2015 Jul-Aug;22(4):273-83. doi: 10.1111/xen.12175. Epub 2015 Jul 2.

PMID:
26134468
5.

Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor.

Wu Y, Sun H, Basta-Pljakic J, Cardoso L, Kennedy OD, Jasper H, Domené H, Karabatas L, Guida C, Schaffler MB, Rosen CJ, Yakar S.

J Bone Miner Res. 2013 Jul;28(7):1575-86. doi: 10.1002/jbmr.1920.

6.

Clinical features and growth hormone receptor gene mutations of patients with Laron syndrome from a Chinese family.

Ying YQ, Wei H, Cao LZ, Lu JJ, Luo XP.

Zhongguo Dang Dai Er Ke Za Zhi. 2007 Aug;9(4):335-8.

PMID:
17706034
7.

Novel growth hormone receptor gene mutation in a patient with Laron syndrome.

Arman A, Yüksel B, Coker A, Sarioz O, Temiz F, Topaloglu AK.

J Pediatr Endocrinol Metab. 2010 Apr;23(4):407-14.

PMID:
20583548
8.

Growth hormone insensitivity: diagnostic and therapeutic approaches.

Kurtoğlu S, Hatipoglu N.

J Endocrinol Invest. 2016 Jan;39(1):19-28. doi: 10.1007/s40618-015-0327-2. Epub 2015 Jun 11. Review.

PMID:
26062520
9.

Identification of a novel mutation in the human growth hormone receptor gene (GHR) in a patient with Laron syndrome.

Gennero I, Edouard T, Rashad M, Bieth E, Conte-Aurio F, Marin F, Tauber M, Salles JP, El Kholy M.

J Pediatr Endocrinol Metab. 2007 Jul;20(7):825-31.

PMID:
17849745
10.

Novel growth hormone receptor mutation in a Chinese patient with Laron syndrome.

Hui HN, Metherell LA, Ng KL, Savage MO, Camacho-Hübner C, Clark AJ.

J Pediatr Endocrinol Metab. 2005 Feb;18(2):209-13.

PMID:
15751611
11.

Clinical and Molecular Features of Laron Syndrome, A Genetic Disorder Protecting from Cancer.

Janecka A, Kołodziej-Rzepa M, Biesaga B.

In Vivo. 2016 Jul-Aug;30(4):375-81. Review.

PMID:
27381597
12.

Characterisation of the xenogeneic immune response to microencapsulated fetal pig islet-like cell clusters transplanted into immunocompetent C57BL/6 mice.

Vaithilingam V, Fung C, Ratnapala S, Foster J, Vaghjiani V, Manuelpillai U, Tuch BE.

PLoS One. 2013;8(3):e59120. doi: 10.1371/journal.pone.0059120. Epub 2013 Mar 15.

13.

Encapsulation, in vitro characterization, and in vivo biocompatibility of Sertoli cells in alginate-based microcapsules.

Luca G, Calvitti M, Nastruzzi C, Bilancetti L, Becchetti E, Angeletti G, Mancuso F, Calafiore R.

Tissue Eng. 2007 Mar;13(3):641-8.

PMID:
17335402
14.

Is the Laron mouse an accurate model of Laron syndrome?

Kopchick JJ, Laron Z.

Mol Genet Metab. 1999 Oct;68(2):232-6. Review. No abstract available.

PMID:
10527674
15.

Parathyroid xenotransplantation without immunosuppression in experimental hypoparathyroidism: long-term in vivo function following microencapsulation with a clinically suitable alginate.

Hasse C, Bohrer T, Barth P, Stinner B, Cohen R, Cramer H, Zimmermann U, Rothmund M.

World J Surg. 2000 Nov;24(11):1361-6.

PMID:
11038207
16.

Xenograft of microencapsulated Sertoli cells for the cell therapy of type 2 diabetes mellitus in spontaneously diabetic nonhuman primates: preliminary data.

Luca G, Cameron DF, Arato I, Mancuso F, Linden EH, Calvitti M, Falabella G, Szekeres K, Bodo M, Ricci G, Hansen BC, Calafiore R.

Transplant Proc. 2014 Jul-Aug;46(6):1999-2001. doi: 10.1016/j.transproceed.2014.06.053.

PMID:
25131093
17.

Growth hormone insensitivity syndrome caused by a heterozygous GHR mutation: phenotypic variability owing to moderation by nonsense-mediated decay.

Gorbenko del Blanco D, de Graaff LC, Visser TJ, Hokken-Koelega AC.

Clin Endocrinol (Oxf). 2012 May;76(5):706-12. doi: 10.1111/j.1365-2265.2011.04304.x.

PMID:
22117696
18.

Encapsulation of porcine pancreatic islets within an immunoprotective capsule comprising methacrylated glycol chitosan and alginate.

Hillberg AL, Oudshoorn M, Lam JB, Kathirgamanathan K.

J Biomed Mater Res B Appl Biomater. 2015 Apr;103(3):503-18. doi: 10.1002/jbm.b.33185. Epub 2014 Jun 11.

PMID:
24915784
19.

A novel growth hormone receptor gene deletion mutation in a patient with primary growth hormone insensitivity syndrome (Laron syndrome).

Yamamoto H, Kouhara H, Iida K, Chihara K, Kasayama S.

Growth Horm IGF Res. 2008 Apr;18(2):136-42. Epub 2007 Aug 28.

PMID:
17728167
20.

Laron syndrome: clinical features, molecular pathology and treatment.

Laron Z, Klinger B.

Horm Res. 1994;42(4-5):198-202.

PMID:
7868073

Supplemental Content

Support Center